2026-06-27T23:52:38Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/83112024-04-29T12:34:45Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Sánchez-Paniagua López, Marta author González Burgos, Elena María author Iglesias Peinado, Irene author Lozano Fernández, Rafael author Gómez-Serranillos Cuadrado, María Pilar author 2020-04-13 Tea made from Camellia sinensis leaves is one of the most consumed beverages worldwide. This systematic review aims to update Camellia sinensis pharmacological activity on metabolic and endocrine disorders. Inclusion criteria were preclinical and clinical studies of tea extracts and isolated compounds on osteoporosis, hypertension, diabetes, metabolic syndrome, hypercholesterolemia, and obesity written in English between 2014 and 2019 and published in Pubmed, Science Direct, and Scopus. From a total of 1384 studies, 80 reports met inclusion criteria. Most papers were published in 2015 (29.3%) and 2017 (20.6%), conducted in China (28.75%), US (12.5%), and South Korea (10%) and carried out with extracts (67.5%, especially green tea) and isolated compounds (41.25%, especially epigallocatechin gallate). Most pharmacological studies were in vitro and in vivo studies focused on diabetes and obesity. Clinical trials, although they have demonstrated promising results, are very limited. Future research should be aimed at providing more clinical evidence on less studied pathologies such as osteoporosis, hypertension, and metabolic syndrome. Given the close relationship among all endocrine disorders, it would be of interest to find a standard dose of tea or their bioactive constituents that would be beneficial for all of them. 2218-273X 10.3390/biom10040603 https://hdl.handle.net/20.500.14352/8311 https://doi.org/10.3390/biom10040603 https://www.mdpi.com/2218-273X/10/4/603 The Pharmacological Activity of Camellia sinensis (L.) Kuntze on Metabolic and Endocrine Disorders: A Systematic Review